Q2 2026 Highlights

VIATRIS™

Q2 2026 Financial Results

Total Revenues
$3.8B

Adjusted EBITDA*
$1.2B

Adjusted EPS*
$0.69

Free Cash Flow*
Ex. Transaction and Restructuring Costs
$449M

"Our second-quarter results reflect another quarter of strong execution and reinforce the momentum we're building across our business. Commercial execution, pipeline progress and the early benefits of our enterprise-wide strategic review continue strengthening our business and improving our financial performance. Our strong first-half results give us the confidence to raise our full-year guidance. We expect a more balanced operating environment in the second half of the year and we remain focused on disciplined execution, investing behind our future growth drivers and creating long-term value for patients and shareholders."

Delivering on Our 2026 Strategic Priorities

2026 Strategic Priorities	Execution
Deliver strong financial performance	Q2 performance ahead of our expectations, with 4% total revenue growth, 8% adjusted EBITDA growth, and 9% adjusted EPS growth operationally
Drive commercial execution, including launches	Strong commercial execution across our global portfolio, led by Greater China and Developed Markets
Advance our pipeline, including regulatory decisions for six product candidates	Received FDA approval for Gwyn Lo™ and several complex injectables, including ferric carboxymaltose
	Cenerimod SLE Phase 3 studies fully enrolled; Selatogrel Phase 3 full enrollment expected in 2026
Execute disciplined and balanced capital allocation	Returned ~$550M of capital to shareholders through early August, including ~$270M share repurchases and ~$280M dividends paid
Target accretive in-market business development	
Evolve our organization and modernize for future growth	On track to deliver identified cost savings, while reinvesting in the business to support future growth

* Non-GAAP Financial Measure. For more information about Non-GAAP financial measures and reconciliations to the closest U.S. GAAP financial measure, as well as risks related to forward-looking statements, please read our Second-Quarter 2026 Financial Results press release on our website.

(1) 2026 Free Cash Flow was $329M. Excluding the impact of transaction-related and restructuring-related costs of $120M, Q2 2026 Free Cash Flow was $449M.

Viatris.com | LinkedIn | @ViatrisInc | @ViatrisInc | YouTube